A clinical trial of the Novovax coronavirus vaccine for children ages 12-17 will begin next week in Jacksonville.
Dr. Michael Koren is with the Jacksonville Center for Clinical Research, which is leading the study here.
Koren said Thursday on First Coast Connect with Melissa Ross that Novovax is different from other vaccines currently in use.
While Johnson & Johnson uses the actual virus, and Pfizer and Moderna use Messenger RNA to trigger the body’s immune response, Novovax uses a different method to fight the coronavirus.
“Novovax manufactures what is known as a protein therapeutic. They genetically engineer the spike protein. With a low concentration of spike protein, we can prepare the immune system to fight COVID-19. “
Koren said the Novovax study was a so-called crossover, which means that each participant received the vaccine by the end of the blind study.
Parents can register their children for the study at jaxresearch.com. The entire interview with Koren is available Thursday on First Coast Connect with Melissa Ross, which will be posted on WJCT News 89.9 on Thursday evening at 8 a.m.
Bill Bortzfield can be reached at [email protected], 904-358-6349 or on Twitter at @BortzInJax.